Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 07.07.2025 1 AJR Am J Roentgenol 2 Ann Surg Oncol 8 BMC Cancer 1 Cancer Res 1 Cancer Sci 1 Chest 2 Clin Cancer Res 3 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Immunol 1 J Thorac Cardiovasc Surg 7 Lung Cancer 3 Oncogene 2 Oncologist 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. HWANG J, Kim PH, You S, Kim YN, et al
   Interreader Agreement of Lung-RADS: A Systematic Review and Meta-Analysis.
   AJR Am J Roentgenol. 2025;224:e2532681.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. BURKHARD-MEIER A, Grube M, Jurinovic V, Agaimy A, et al
   Does Size Outweigh Number in Predicting Survival After Pulmonary Metastasectomy for Soft Tissue Sarcoma? Insights from a Retrospective Multicenter Study.
   Ann Surg Oncol. 2025;32:5948-5956.
   PubMed         Abstract available
   
   
3. PENG Y, Jia N, Wang J, Dong S, et al
   Analysis of Multiple Programmed Cell Death Patterns and Functional Validations of Apoptosis-Associated Genes in Lung Adenocarcinoma.
   Ann Surg Oncol. 2025;32:6005-6022.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. FAIZI MK, Qiang Y, Wei Y, Qiao Y, et al
   Deep learning-based lung cancer classification of CT images.
   BMC Cancer. 2025;25:1056.
   PubMed         Abstract available
   
   
5. ZHANG J, Wu Z, Wang S, Sun Y, et al
   Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer.
   BMC Cancer. 2025;25:1070.
   PubMed         Abstract available
   
   
6. LIU M, Yang F, Tang B, Xin X, et al
   Steps towards overcoming challenges in clinical practice at 1.5T MR-Linac for lung cancer adaptive radiotherapy.
   BMC Cancer. 2025;25:1034.
   PubMed         Abstract available
   
   
7. ZHAO L, Xiong Q, Long Y, Hu H, et al
   Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study.
   BMC Cancer. 2025;25:1136.
   PubMed         Abstract available
   
   
8. LONG L, Jiang L, Teng Y, Yang D, et al
   Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer.
   BMC Cancer. 2025;25:1077.
   PubMed         Abstract available
   
   
9. GUO LW, Lyu ZY, Liu Y, Meng QC, et al
   The probability of lung cancer in patients with pulmonary nodules detected via low-dose computed tomography screening in China.
   BMC Cancer. 2025;25:1058.
   PubMed         Abstract available
   
   
10. WANG XC, Xu XL, Wang SY, Cheng H, et al
    Nomogram based on the advanced lung cancer inflammation index and other relevant clinical factors for patients with cervical squamous cell carcinoma undergoing concurrent chemoradiotherapy.
    BMC Cancer. 2025;25:1043.
    PubMed         Abstract available
    
    
11. NIU Y, Jia HB, Li XM, Huang WJ, et al
    Deep learning radiomics and mediastinal adipose tissue-based nomogram for preoperative prediction of postoperative? brain metastasis risk in non-small cell lung cancer.
    BMC Cancer. 2025;25:1133.
    PubMed         Abstract available
    
    

    
    Cancer Res

12. SEN U, Coleman C, Gandhi N, Jethalia V, et al
    SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.
    Cancer Res. 2025;85:2485-2503.
    PubMed         Abstract available
    
    

    
    Cancer Sci

13. HOSOYA K, Ozasa H, Yoshida H, Ajimizu H, et al
    Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
    Cancer Sci. 2025;116:1883-1896.
    PubMed         Abstract available
    
    

    
    Chest

14. MATHEY-ANDREWS CA, Potter AL, Srinivasan D, Senthil P, et al
    Segmentectomy versus Lobectomy for Patients with 2-3cm Non-Small-Cell Lung Cancer.
    Chest. 2025 Jun 29:S0012-3692(25)00812-8. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. JANG HJ, Patel M, Wang DY, Kang SW, et al
    Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.
    Clin Cancer Res. 2025;31:2639-2654.
    PubMed         Abstract available
    
    
16. ROLFO C, O'Brate A, Menzel C, Bruns R, et al
    Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
    Clin Cancer Res. 2025;31:2675-2684.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

17. SAKATA Y, Saito G, Sakata S, Yamaguchi T, et al
    Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).
    Clin Lung Cancer. 2025 Jun 10:S1525-7304(25)00129.
    PubMed         Abstract available
    
    
18. BAZHENOVA L, Hodgson JG, Camidge DR, Langer CJ, et al
    Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
    Clin Lung Cancer. 2025 Jun 6:S1525-7304(25)00128.
    PubMed         Abstract available
    
    
19. HENRIKSEN MB, Hilberg O, Juul C, Thomsen R, et al
    Maximizing Lung Cancer Screening in High-Risk Population Leveraging ML-Developed Risk-Prediction Algorithms: Danish Retrospective Validation of LungFlag.
    Clin Lung Cancer. 2025 Jun 4:S1525-7304(25)00130.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

20. DENG HY, Daoud A
    Systematic lymph node dissection for early-stage non-small cell lung cancer: One size does not fit all.
    Eur J Cardiothorac Surg. 2025 Jul 2:ezaf147. doi: 10.1093.
    PubMed        
    
    
21. ALSHAMMARI A, Ashraf M, De Sousa P, Naruka V, et al
    Incidence and resource burden for the management of computed tomography-detected ground glass opacities at a tertiary lung cancer service in the United Kingdom.
    Eur J Cardiothorac Surg. 2025 Jul 4:ezaf223. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

22. DENG Y, Guo C, Zhang T, Chen Y, et al
    Comprehensive analysis of a real-world cohort identifies geranylgeranyl diphosphate synthase 1 as a predictor of chemoresistance in small cell lung cancer.
    Int J Cancer. 2025 Jul 4. doi: 10.1002/ijc.70036.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

23. ZHOU L, Sun J, Xie C, Kang K, et al
    Low-dose radiotherapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: 3-year follow-up of a multicenter, single-arm, phase 2 trial (MATCH).
    Int J Radiat Oncol Biol Phys. 2025 Jul 1:S0360-3016(25)04508.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

24. YILDIZ O, Eryilmaz MK, Gurbuz AF, Kaya BE, et al
    Small cell lung cancer differentiation in patients with driver mutant non-small cell lung cancer: a single center experience.
    J Cancer Res Clin Oncol. 2025;151:199.
    PubMed         Abstract available
    
    

    
    J Immunol

25. SNYDER M, Wang Z, Lara B, Fimbres J, et al
    The aryl hydrocarbon receptor controls IFN-gamma-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.
    J Immunol. 2025;214:413-432.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

26. INAN GA, Aksakal AK, Ayrak FB, Ergiden C, et al
    Interpreting survival comparisons in stage III non-small cell lung cancer: Performance bias and the need for subgroup-specific analysis.
    J Thorac Cardiovasc Surg. 2025 Jul 2:S0022-5223(25)00473.
    PubMed        
    
    

    
    Lung Cancer

27. FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al
    Transforming lung cancer diagnosis: the role of robotic-assisted bronchoscopy in early detection and staging.
    Lung Cancer. 2025;206:108646.
    PubMed         Abstract available
    
    
28. ZENKE Y, Niho S, Toi Y, Yamaguchi M, et al
    Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
    Lung Cancer. 2025;206:108633.
    PubMed         Abstract available
    
    
29. TACHIHARA M, Shoda H, Akazawa Y, Ota T, et al
    Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).
    Lung Cancer. 2025;206:108637.
    PubMed         Abstract available
    
    
30. OLLILA H, Tidjani A, Park BJ, Jones DR, et al
    Nonagenarians: Outcomes after lung cancer surgery.
    Lung Cancer. 2025;206:108632.
    PubMed         Abstract available
    
    
31. PETERS BJ, van Geffen E, Hilarius D, Bohringer S, et al
    The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell Lung cancer.
    Lung Cancer. 2025;206:108642.
    PubMed         Abstract available
    
    
32. WANG H, Wang L, Gao N, Li H, et al
    Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2025;206:108641.
    PubMed         Abstract available
    
    
33. SHI Y, Chen R, Xiong Y, Geng R, et al
    MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review.
    Lung Cancer. 2025;206:108634.
    PubMed         Abstract available
    
    

    
    Oncogene

34. GAO Y, Li B, Jin Y, Cheng J, et al
    Spatial multi-omics profiling of breast cancer oligo-recurrent lung metastasis.
    Oncogene. 2025 Apr 15. doi: 10.1038/s41388-025-03388.
    PubMed         Abstract available
    
    
35. OH YT, Chen Z, Wang D, Ramalingam SS, et al
    Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells.
    Oncogene. 2025;44:2315-2327.
    PubMed         Abstract available
    
    
36. TAKUMIDA H, Saito A, Okabe Y, Terasaki Y, et al
    Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ASCL1 and NEUROD1 in small cell lung cancer.
    Oncogene. 2025 Jul 1. doi: 10.1038/s41388-025-03481.
    PubMed         Abstract available
    
    

    
    Oncologist

37. TM A, Raj L, Nair P, Vincent A, et al
    Utility And Real-World Clinical Outcomes Of Next-Generation Sequencing In Advanced Non-Small-Cell Lung Cancer In South Indian Population.
    Oncologist. 2025 Jul 1:oyaf168. doi: 10.1093.
    PubMed         Abstract available
    
    
38. FRISCH A, Martin E, Kim SY, Riess JW, et al
    KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.
    Oncologist. 2025;30:oyaf153.
    PubMed         Abstract available
    
    

    
    PLoS One

39. ZHONG W, Yuan H, Li T, Jin X, et al
    Therapeutic patterns and outcomes in older patients (aged >/= 65 years) with stage III inoperable non-small cell lung cancer (NSCLC): An investigational study from the SEER database.
    PLoS One. 2025;20:e0327458.
    PubMed         Abstract available
    
    
40. ABDULKADER-NALLIB I, Cameselle-Teijeiro JM, Lesende-Rodriguez I, Perez-Becerra R, et al
    Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain).
    PLoS One. 2025;20:e0326336.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.